Every material Form 8-K Azenta filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Azenta's subsidiary Azenta Germany GmbH signed a definitive agreement on December 23, 2025 to sell B Medical Systems S.À R.L. to Thelema S.À R.L. for $63 million, with closing expected on or before March 31, 2026. The buyer's completion depends on securing final residual financing, and the filing states there is no assurance that condition will be met. The transaction is with a related party, since Thelema's majority owner is Luc Provost, Azenta's Vice President and CEO of B Medical.
Purchase price is $63 million: $9 million deposited with Azenta Germany GmbH and $54 million due on or before March 31, 2026.
Thelema's financing for the acquisition is a condition to completion; if not satisfied by March 31, 2026, either party may terminate.
If terminated for the financing condition, Azenta Germany GmbH will keep $5 million of the deposit as a break-up fee.
Related party: Luc Provost, Azenta Vice President and CEO of B Medical, is Thelema's majority owner; the filing says terms were negotiated at arm's length after a competitive auction.
Azenta reported fourth-quarter revenue of $159 million, up 6% year over year, and fiscal 2025 revenue of $594 million, up 4%. Q4 diluted EPS from continuing operations was $1.11, compared with a loss of $0.04 a year earlier, though that figure includes a one-time $45.6 million tax benefit. The company expects fiscal 2026 organic revenue growth of 3% to 5% and adjusted EBITDA margin expansion of about 300 basis points.
Q4 fiscal 2025 revenue was $159 million, up 6% year over year, and 4% on an organic basis.
Q4 diluted EPS from continuing operations was $1.11 versus a loss of $0.04, including a one-time $45.6 million tax benefit.
Fiscal 2025 total diluted EPS was a loss of $1.30, compared with a loss of $3.10 in fiscal 2024.
Fiscal 2026 guidance: organic revenue growth of 3% to 5% and adjusted EBITDA margin expansion of about 300 basis points.
Azenta reported fiscal third-quarter 2025 results for the quarter ended June 30, 2025. Revenue from continuing operations was $144 million, flat year over year, while adjusted EBITDA margin rose to 12.3% from 9.7%. A $50 million non-cash impairment charge tied to discontinued operations pushed total diluted EPS to ($1.15), and the company reiterated its full-year fiscal 2025 guidance.
Revenue was $144 million, flat year over year; organic revenue declined 2%.
Diluted EPS from continuing operations was $0.01 versus ($0.00) a year earlier; non-GAAP diluted EPS was $0.19 versus $0.14.
Total diluted EPS was ($1.15) versus ($0.12), including ($1.17) from discontinued operations due to a $50 million non-cash impairment charge.
Full-year fiscal 2025 guidance was reiterated: organic revenue growth of 3% to 5% and adjusted EBITDA margin expansion of about 300 basis points.
Azenta said Vice President and Chief Accounting Officer Violetta Hughes will leave the company and its subsidiaries effective August 6, 2025, to pursue opportunities outside the company. The filing states the resignation is not the result of any disagreement with the company or its board on operations, policies, practices, controls, or financial or accounting matters, and that she will work through the separation date to transition her duties.
Violetta Hughes resigned as Vice President and Chief Accounting Officer (Principal Accounting Officer) and from all subsidiary director and officer roles.
Notice was received June 27, 2025; the separation date is August 6, 2025.
The company states the departure was not due to any disagreement on financial, accounting, or controls matters.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Azenta filing is on SEC EDGAR ↗. 8-K briefs of other companies →